SECFilings

CardiolRx™ is being developed to enter the validated, high-value recurrent pericarditis market for the reduction in the risk of pericarditis recurrence where the first approved therapy has already demonstrated blockbuster-scale commercial potential. Importantly, CardiolRx™ is positioned as a differentiated therapeutic option within this market offering a distinct profile relative to existing treatments. $CRDL

🎧 New episode of @Siemens' #DigitalizationTechTalks podcast is live, featuring our own @iamAbeDyck. 👉 siemens.fm/public/podcast… Abe joined Don Mack and Cole Lewis of Siemens to discuss how chemical recycling is moving from lab-scale research to real-world industrial deployment. The conversation covers pilot plant operations, continuous processing, and feedstock challenges, along with the role of data collection, process automation, simulation, and AI in helping reduce risk, improve decision-making, and accelerate the path to commercial reality. $ADUR #CleanTech #EcoInnovation #ChemicalRecycling #Digitalization

$AIRDF Rocket Doctor's mission aligns with its actions - providing health care for underserved populations. Expanding its program in NYC, advocating for Medicare telehealth, reaching 21 million covered lives. We review the big picture for investors here. secfilings.com/news/when-the-…

$ADUR Aduro advances its paraffinic crude program to technology demonstration, progressing alongside its plastic recycling business that currently accounts for almost all of the company's value. Unlocking another large vertical... read about it here. secfilings.com/news/aduro-s-o…

$AIRDF After a successful pilot, Rocket Doctor is expanding its EngageWell engagement in NYC with new funding. More than 400 underserved New Yorkers were reached through physician-led virtual urgent care. The next phase works toward billing Medicaid directly where eligible.

$OCO.NE (long position) Oroco Reports Select Surface Sample of 7.57% Copper and Completion of Drone Magnetic Survey at Vainilla Highlights Mapping and sampling have advanced the definition of three principal mineralized areas: El Platano, Mazomique and Cristina. One selective rock-chip sample from a historical working at El Platano returned 7.57% copper; the sample is not representative of the overall grade or continuity of mineralization. El Platano is interpreted as a mineralized breccia body hosting copper-iron oxides, secondary copper minerals, precious metal anomalies, quartz-tourmaline brecciation within a broad propylitic alteration halo in andesitic volcanics. Mapping surrounding Mazomique has identified magnetite-pyrite-chalcopyrite mineralization and copper oxides associated within exo-skarns exposed in previous mining operations. At Cristina, a structurally controlled breccia is host to anomalous gold, silver, copper and lead. A property-wide, high-resolution drone magnetic survey has been completed to assist in defining structural, intrusive, porphyry and skarn-related exploration targets.

Our program evaluating Hydrochemolytic™ Technology for highly paraffinic crude oils has reached a new stage, advancing toward continuous-flow process development. 👉 investors.adurocleantech.com/press-releases… Highlights: - Feedstock secured from multiple Uinta Basin sources, supporting our next test campaigns - New lab-scale continuous-flow unit completed, dedicated to the paraffinic crude program - London facility expanded by ~4,600 sq ft to support equipment and operating activities - Operations consolidated from Sarnia to London, bringing our team together at one site Paraffinic and waxy crudes are estimated to make up 20%–33% of global crude production. This work advances our Technology Demonstration toward Process Development and Optimization, building the operating envelope and data needed to guide next steps. "With feedstocks secured from multiple sources and continuous-flow capability now in place, we can evaluate the technology under sustained operating conditions and build the evidence needed to guide the next phase of development," said Ofer Vicus, CEO. $ADUR #CleanTech #EcoInnovation #HeavyCrude #UintaBasin

$VLTLF $LIB.V Two bipartisan bills, EMRTAI and CHARM, easily cleared the House committee. Focus on recovery of critical minerals from waste streams. Exactly what LibertyStream's lithium extraction business does. We look at the implications here. secfilings.com/news/washingto…

$ADUR Four firms. Four Buys. No holds, no sells. The spread is wide, $22 to $46, and the stock is at $13.40. Even the lowest target on the street implies roughly 64% upside. The highest implies about 243%. The average of the four sits near $30.70, or roughly 129% above where the shares closed. Every one of them is built on inputs at the low end of the plausible range, with the highest price target assuming c. 600k tons of Hydrocarbons being upgraded via @AduroCleanTech HCT platform by 2035 across the plastics and the Parrafinc veritals. That is less than a 0.2% of each respective market by 2035!!

$LEEEF $LEEF LEEF Brands vertically integrates its cannabis supply chain, growing pesticide-free at Salisbury Canyon Ranch and set to acquire a processing facility to further boost margins for its leading concentrates business. Details here. secfilings.com/news/leef-bran…

Recurrent pericarditis has emerged as a highly attractive commercial opportunity within cardiovascular medicine—supported by both strong clinical demand and clear market validation. For @CardiolRx, this validated market provides a compelling foundation as we advance CardiolRx™—with the goal of delivering a differentiated and accessible treatment option. $CRDL #RecurrentPericarditis #Biotech

A Wall Street firm just put a $30 target on $ADUR (~$13 today). Water-based chemistry turning waste plastic into recycled naphtha. ROTH calls 300-400K tonnes of capacity by 2035 the conservative case. My largest position. DYOR. @TheLongInvest

More beautiful liters of distillate from the summer harvest at Salisbury Canyon Ranch. As we continue refining our cultivation, genetics, and extraction processes, the quality keeps improving. The first batches from the farm passed California's elevated CAT4 pesticide panel and tested at 94.7% THC and 98.5% total cannabinoids. The potency, clarity, and color speak for themselves. If you're a California brand, distributor, or dispensary chain looking for a reliable supply of premium, clean distillate, we'd love to talk. Let us know how we can help. $LEEF $LEEEF

$ADUR Investing.com Roth/MKM initiated coverage on Aduro Clean Technologies Inc. (NASDAQ:ADUR) with a buy rating and a price target of $30.00: ca.investing.com/news/stock-mar…

Highly paraffinic crude is abundant. For years, refiners have accepted that processing it means trade-offs in yield, quality, and economics. Our Chief Revenue Officer, @EricAppelm6595, will challenge that assumption at @HydrocarbonProc's International Refining and Petrochemical Conference (IRPC) this October. His session, "A New Technology to Unlocking Value from Highly Paraffinic Crude Oil," covers the underlying chemistry and what feedstock flexibility means for refiners evaluating it as a strategic lever. 📅 October 8–9 | Hyatt Regency Houston West, Houston, TX ⏰ Early bird registration closes August 28 — register your team now: hpirpc.com/registration/ $ADUR #HPIRPC26 #Refining #ParaffinicCrude

Interstate commerce has the potential to reshape the cannabis industry and could have an outsized impact on operators like LEEF. Thank you to @jesseredmond and @anandastrategy for a thoughtful discussion on the legal pathways, market implications, and what operators should be watching as the regulatory landscape evolves. If you missed it live, the replay is available here: x.com/i/spaces/1DGle…

The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV The Precision Peptide Company Inc. applauds today's vote by the U.S. Food and Drug Administration's ("FDA") Pharmacy Compounding Advisory Committee, which recommended that BPC-157 and KPV be considered for inclusion on the FDA's 503A Bulks List. While the recommendation is advisory and subject to final FDA review, the Company believes it represents a positive step toward improving patient access to quality-focused, professionally compounded peptide therapies. If ultimately adopted by the FDA, today's advisory committee recommendation represents a significant step toward allowing U.S. patients to legally access physician-prescribed BPC-157 through regulated compounding pharmacies, replacing much of the current reliance on unregulated sources. CSE: $BPC | OTC:PNGAF

$PNGAF $HIMS $ENHA Major development in the peptide industry: FDA panel recommends BPC-157 for compounding. Three companies offering different risk/reward are positioned to capitalize should the full FDA accept the recommendation. Check out the details: secfilings.com/news/fda-panel…

Rocket Doctor Inc. was selected as one of Canada's Top 100 AI & Tech Startups for ALL IN 2026, out of more than 330 applicants. More than 350 physicians. More than 750,000 patient visits across North America. Showcasing in Montréal Sept 16-17. $AIRDF | CSE: $AIDR youtube.com/shorts/kJVaYPS…

Oroco (TSX-V: $OCO | OTCQB: $ORRCF) has published its Q2 2026 Recap. Highlights: Charles Cryer appointed CEO • Phase 2 drilling advancing, third rig now in the South Zone • 22 holes / 6,709m completed to date Full newsletter in reply 👇 #Copper #Mining #Oroco